Description
Subtitle: Why they must help us improve the evidence base; Editorial in which the authors discuss drug clinical trial data submitted to the US Food and Drug Administration and call for regulators to correct misleading information published in the medical literature.Citation
Doshi, P. & Godlee, F. (2017). The wider role of regulatory scientists. BMJ, 357. DOI: 10.1136/bmj.j1991Keyword
ethical responsibility of regulatory scientistsAccess to Information
Clinical Trials as Topic
Disclosure
Social Responsibility
United States. Food and Drug Administration--ethics
Identifier to cite or link to this item
http://hdl.handle.net/10713/6593ae974a485f413a2113503eed53cd6c53
10.1136/bmj.j1991
Scopus Count
Collections
Related articles
- FDA approval of paroxetine for menopausal hot flushes.
- Authors: Orleans RJ, Li L, Kim MJ, Guo J, Sobhan M, Soule L, Joffe HV
- Issue date: 2014 May 8
- Precautionary harm disclosure in clinical trials.
- Authors: Wu KC
- Issue date: 2009 Aug
- COX-2-dependent and independent effects of COX-2 inhibitors and NSAIDs on proatherogenic changes in human monocytes/macrophages.
- Authors: Voloshyna I, Kasselman LJ, Carsons SE, Littlefield MJ, Gomolin IH, De Leon J, Reiss AB
- Issue date: 2017 Mar
- Some key points emerging from the COX-2 controversy.
- Authors: Urquhart J
- Issue date: 2005 Mar
- Lack of Small Intestinal Dysbiosis Following Long-Term Selective Inhibition of Cyclooxygenase-2 by Rofecoxib in the Rat.
- Authors: Lázár B, Brenner GB, Makkos A, Balogh M, László SB, Al-Khrasani M, Hutka B, Bató E, Ostorházi E, Juhász J, Kemény Á, László T, Tiszlavicz L, Bihari Z, Giricz Z, Szabó D, Helyes Z, Ferdinandy P, Gyires K, Zádori ZS
- Issue date: 2019 Mar 15